Cleveland Clinic chemists consolidated two separate drug-screening assays into a single 34-analyte LC-MS/MS urine panel, published in the Journal of Chromatography B. By separating compounds and identifying each by precise mass transitions, the method avoids the cross-reactivity that produces false positives in antibody-based screens. The validated panel processes up to 1,000 patient specimens a week without losing sensitivity.

This episode was generated by AI from the cited research paper.